Maps the immune system at clinical scale from a single blood sample.
| Date | Round | Amount |
|---|---|---|
| Jun 2026 | Series A IMU Biosciences extended its Series A to over $53M in an oversubscribed round co-led by IQ Capital and Molten Ventures, with the British Business Bank and Meltwind. | $53M |
Tap an investor to see what else they have backed.
Data is community-curated and may be incomplete.